Arena Pharmaceuticals, Inc. (ARNA) Posts Q2 Loss of 12c/Share, Wider than Views
Tweet
Share
E-mailGet Alerts ARNA Hot Sheet
Price: $99.98 --0%
Financial Fact:
Gain from valuation of derivative liabilities: 0
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Gain from valuation of derivative liabilities: 0
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported Q2 EPS of ($0.12), $0.04 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $22 million versus the consensus estimate of $7.38 million.
For earnings history and earnings-related data on Arena Pharmaceuticals, Inc. (ARNA) click here.
For earnings history and earnings-related data on Arena Pharmaceuticals, Inc. (ARNA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Hitachi Ltd. (HIT) Misses Q2 EPS by 7c
- zSpace, Inc. (ZSPC) Reports Q2 results
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
